Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Aytu Biopharma (AYTU) Shares Outstanding (Weighted Average) (2016 - 2025)

Aytu Biopharma (AYTU) has disclosed Shares Outstanding (Weighted Average) for 15 consecutive years, with $12.6 million as the latest value for Q4 2025.

  • Quarterly Shares Outstanding (Weighted Average) rose 107.04% to $12.6 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $12.6 million through Dec 2025, up 107.04% year-over-year, with the annual reading at $6.3 million for FY2025, 13.39% up from the prior year.
  • Shares Outstanding (Weighted Average) for Q4 2025 was $12.6 million at Aytu Biopharma, up from $9.4 million in the prior quarter.
  • The five-year high for Shares Outstanding (Weighted Average) was $16.7 million in Q2 2021, with the low at $15571.0 in Q2 2025.
  • Average Shares Outstanding (Weighted Average) over 5 years is $5.8 million, with a median of $5.5 million recorded in 2024.
  • The sharpest move saw Shares Outstanding (Weighted Average) plummeted 99.82% in 2021, then soared 11590.43% in 2022.
  • Over 5 years, Shares Outstanding (Weighted Average) stood at $24105.0 in 2021, then skyrocketed by 11590.43% to $2.8 million in 2022, then skyrocketed by 129.96% to $6.5 million in 2023, then fell by 5.86% to $6.1 million in 2024, then skyrocketed by 107.04% to $12.6 million in 2025.
  • According to Business Quant data, Shares Outstanding (Weighted Average) over the past three periods came in at $12.6 million, $9.4 million, and $15571.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.